Aldeyra Therapeutics
ALDX
Aldeyra Therapeutics (ALDX) news
Recent news
Aldeyra Therapeutics - FDRR to appeal March 16, 2026 complete response letter denying NDA for Reproxalap
AInvest Wire · Sep 29, 2026Aldeyra Therapeutics - To submit formal dispute resolution request to FDA for Reproxalap
AInvest Wire · Sep 29, 2026Aldeyra extends cash runway into 2029 on $45.1M reserves
AInvest Wire · Sep 29, 2026Aldeyra to meet FDA office of new drugs in 4Q 2026
Aldeyra Therapeutics has announced plans to meet with the U.S. Food and Drug Administration’s Office of New Drugs in the fourth quarter of 2026. The meeting is intended to discuss the company’s ongoing drug development programs and regulatory pathways for its therapeutic candidates. While specific…
AInvest Wire · Sep 29, 2026Aldeyra to file dispute request for Reproxalap with FDA
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.